Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11980723 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Rena G, et al. (2002) Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J 21, 2263-71 11980723
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T24-p - FOXO1A (human) ▲
Orthologous residues
FOXO1A (human): T24‑p, FOXO1A (mouse): T24‑p, FOXO1A (rat): T24‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'stem, embryonic', 293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase

S256-p - FOXO1A (human) ▲
Orthologous residues
FOXO1A (human): S256‑p, FOXO1A (mouse): S253‑p, FOXO1A (rat): S250‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'stem, embryonic', 293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase

S319-p - FOXO1A (human) ▲
Orthologous residues
FOXO1A (human): S319‑p, FOXO1A (mouse): S316‑p, FOXO1A (rat): S313‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  'stem, embryonic', 293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase

S322-p - FOXO1A (human) ▲
Orthologous residues
FOXO1A (human): S322‑p, FOXO1A (mouse): S319‑p, FOXO1A (rat): S316‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  'stem, embryonic', 293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK1-A (human)
 Comments:  S319 phosphorylation by Akt promotes the sequential phosphorylation of S322 and S325 by CK1
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Comments:  Alanine mutations of S322 and S325 decrease rate of nuclear exclusion

S325-p - FOXO1A (human) ▲
Orthologous residues
FOXO1A (human): S325‑p, FOXO1A (mouse): S322‑p, FOXO1A (rat): S319‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  'stem, embryonic', 293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK1-A (human)
 Comments:  S319 phosphorylation by Akt promotes the sequential phosphorylation of S322 and S325 by CK1
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Comments:  Alanine mutations of S322 and S325 decrease rate of nuclear exclusion

S329-p - FOXO1A (human) ▲
Orthologous residues
FOXO1A (human): S329‑p, FOXO1A (mouse): S326‑p, FOXO1A (rat): S323‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'stem, embryonic', 293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human

S318-p - FOXO3A (human) ▲
Orthologous residues
FOXO3A (human): S318‑p, FOXO3A (mouse): S317‑p, FOXO3A (rat): S317‑p

S321-p - FOXO3A (human) ▲
Orthologous residues
FOXO3A (human): S321‑p, FOXO3A (mouse): S320‑p, FOXO3A (rat): S320‑p


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.